Rogier Thurlings (photo l) is rheumatologist and Peter van Lent (photo r) is workgroup leader within the section Experimental Rheumatology. They take part in the 'inflammatory diseases' research theme of the Radboudumc. Almost 6 million Euro has been granted to the project ‘ADIPOA-2’ by the EU’s Horizon 2020 research funding programme. 360k Euro is available for their studies at the Radboudumc. ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA (http://adipoa2.eu/).
Synopsis of the project
Osteoarthritis (OA) is an incurable and debilitating disease. It has been identified as the world’s eleventh highest contributor to disability and affects over 70 million Europeans. There is currently no treatment to prevent progression of the disease. ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipo aspiration
ADIPOA-2 is developing a novel cellular therapy to treat osteoarthritis. The Adipoa-2 team comes from a variety of backgrounds and academic disciplines. They share an interest in good science for the service of public health, and have been selected and recruited specifically to cover all angles a project like Adipoa-2 requires.
<< back to overview news items